Indolebenzamide derivatives and medicinal applications thereof
By constructing dopamine and 5-HT1A receptor models, we screened out highly active small molecule compounds of indolinamide derivatives, which solved the problems of poor efficacy and side effects of existing antischizophrenia drugs on negative symptoms, and achieved the goal of treating 5-HT1A receptors. -Effective inhibition of HT1A receptors provides new drugs for the treatment of neuropsychiatric diseases.
Patent Information
- Application Number
- CN201010254261.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2010-08-16
- Publication Date
- 2012-03-14
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antischizophrenia drugs have poor efficacy on negative symptoms and have side effects, such as extrapyramidal symptoms and granulocytopenia. It is of great significance to develop new 5-HT1A receptor antagonists with low toxicity and side effects.
Using the crystal structure of adrenergic β2 receptor as a template to construct dopamine receptor and 5-HT1A receptor models, through molecular dynamics simulation and active site detection, small molecule compounds of indole benzamide derivatives with high activity were screened out. For the preparation of 5-HT receptor inhibitors.
The obtained compound has an inhibitory effect on 5-HT1A receptors and has the potential to be used to treat neuropsychiatric diseases such as schizophrenia and Parkinson's disease caused by dysfunction of the dopamine and 5-HT systems, providing a novel structure, low toxicity and side effects. Treatment options.